Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
PKAγ cat CRISPR/Cas9 KO Plasmid (h): sc-400874
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- PKAγ cat CRISPR/Cas9 Knockout (KO) Plasmid (h) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the PKAγ cat genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: PKAγ cat Antibody (A-4): sc-514087
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
PKAγ cat CRISPR/Cas9 KO Plasmid (h) | sc-400874 | 20 µg | $397.00 |
Overview
PRKACG encodes the gamma catalytic subunit of cAMP-dependent protein kinase A (PKAγ), a serine/threonine kinase that phosphorylates diverse substrates to translate cAMP signals into cellular responses. Through regulation by PKA regulatory subunits and A-kinase anchoring proteins, PKAγ helps control signal compartmentalization and modulates processes including metabolism, transcriptional programs, cytoskeletal dynamics, and ion channel activity. This kinase activity intersects with GPCR–adenylyl cyclase–cAMP signaling and downstream pathways such as CREB-dependent gene expression and cross-talk with MAPK networks. Dysregulation of cAMP/PKA signaling is implicated in multiple disease-relevant phenotypes, including altered proliferative signaling, endocrine and metabolic perturbations, and changes in neuronal excitability, supporting mechanistic studies of PRKACG function in human cells.
PKAγ cat CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the PRKACG gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the PRKACG together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the PRKACG open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish PKAγ cat protein expression.
This CRISPR knockout system enables efficient generation of PRKACG-deficient cell models for investigation of PKAγ cat signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting PRKACG exon(s) critical for PKAγ cat function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple PRKACG genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by PKAγ cat CRISPR/Cas9 KO Plasmid (h) and PKAγ cat CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the PRKACG locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by PKAγ cat HDR Plasmid (h) and PKAγ cat HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by PRKACG homology arms to support homology-directed repair at defined PRKACG target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.